70 reports of this reaction
1.8% of all GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE reports
#10 most reported adverse reaction
SINUSITIS is the #10 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, manufactured by RB Health (US) LLC. There are 70 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE to SINUSITIS. This represents approximately 1.8% of all 3,854 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE who experience sinusitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SINUSITIS is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to sinusitis, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE:
The following drugs have also been linked to sinusitis in FDA adverse event reports:
SINUSITIS has been reported as an adverse event in 70 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SINUSITIS accounts for approximately 1.8% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, making it a notable side effect.
If you experience sinusitis while taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.